New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For BMY;PFE;DUF;CG;HLF;CALM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | all recent news | >>
November 26, 2014
13:25 EDTBMYAchillion to benefit from Bristol-Myers CRL, says FBR Capital
FBR Capital expects Achillion (ACHN) to benefit from the complete response letter that the FDA sent to Bristol-Myers (BMY) on its daclatasvir HCV drug. The firm thunks the letter increases the value of GT-3 HCV patients for Achillion. FBR says that GT-3 patients constitute 5% of HCV patients in the U.S. and significantly higher in Europe. It keeps an Outperform rating on Achillion.
11:38 EDTBMYBristol-Myers receives CRL from FDA for daclatasvir
Subscribe for More Information
11:36 EDTBMYBristol-Myers receives CRL from FDA for daclatasvir
Subscribe for More Information
10:43 EDTPFEMylan calls active after called 'most likely' Pfizer takeover target
Subscribe for More Information
10:34 EDTPFEMylan advances after called 'most likely' Pfizer takeover target
Subscribe for More Information
08:20 EDTHLFAckman says Herbalife short thesis reinforced by recent developments
"Recent developments at Herbalife reinforce our short thesis that HLF is an illegal pyramid that will collapse or otherwise be shut down by regulators," Bill Ackman stated in Pershing Square Holdings' quarterly letter to shareholders, which was released last night. "We continue to believe that the expiration of HLF’s $1.15B credit facility in 2016 is a potential catalyst for further stock price declines, as we are skeptical that the company will be able to access the credit markets in order to refinance or replace this facility," Ackman added. In the letter, Ackman also confirmed that the fund is currently doing due diligence on Actavis (ACT) to determine whether it should remain a long-term holder following the company's deal to acquire Allergan (AGN), noting that Pershing had recently met with the CEO of Actavis and were "impressed with him and his business plan for the combined company." Remarking on some of his other notable holdings, Ackman stated that Canadian Pacific’s (CP) transformation has been "nothing short of remarkable," that he believes the acquisition of Tim Hortons (THI) will create significant long-term value for Burger King (BKW) shareholders, and that early returns from Air Products' (APD) transformation are "promising."
07:48 EDTPFEMylan now most likely takeover target for Pfizer, says Jefferies
Jefferies believes Mylan (MYL), following its combination with Abbott's (ABT) Developed Markets Established Products business, is now the most likely takeover target of Pfizer (PFE). The firm thinks Pfizer management is highly motivated to either merge with, invert into or acquire a foreign company. It believes Actavis (ACT) and AstraZeneca (AZN) are off the table as potential Pfizer targets given the former's takeover of Allergan (AGN) and latter's oncology deal with Merck KGaA (MKGAY). Jefferies calls GlaxoSmithKline (GSK) the "wild card" potential takeover target for Pfizer. The firm estimates Pfizer could pay a 25% premium for Mylan and have the deal be highly accretive.
06:56 EDTCGEthos to sell Tiger Automotive to Carlyle Group, Old Mutual
Subscribe for More Information
November 25, 2014
18:18 EDTHLFOn The Fly: After Hours Movers
Subscribe for More Information
17:05 EDTHLFHerbalife CEO Michael Johnson raises personal share holding in company
Subscribe for More Information
17:02 EDTHLFHerbalife up 1.5% to $42.50 after report CEO exercises options
Subscribe for More Information
16:59 EDTHLFHerbalife CEO exercises 750K stock options, CNBC's Scott Wapner says
Subscribe for More Information
November 24, 2014
18:16 EDTCGCarlyle Group looks to raise $5B for long life fund, Bloomberg says
Carlyle Group is looking to raise as much as $5B for a fund that can hold stakes in companies for up to 20 years, Bloomberg reports. Reference Link
09:00 EDTBMYBristol-Myers, Five Prime announce clinical collaboration for Opdivo, FPA008
Subscribe for More Information
07:46 EDTPFEPfizer seen set to move on from AstraZeneca as restrictions lift, Telegraph says
Subscribe for More Information
November 19, 2014
10:00 EDTHLFOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:52 EDTBMY, PFEInforma Business Information to hold a conference
Subscribe for More Information
07:37 EDTCGCitigroup to hold a conference
Global Financial Conference is being held in Singapore on November 19-20.
06:14 EDTHLFHerbalife initiated with a Buy at BTIG
Subscribe for More Information
06:07 EDTBMYBristol-Myers' Opdivo for melanoma shows positive Phase 3 results
Subscribe for More Information
November 18, 2014
08:33 EDTPFEPfizer announces availability of Trumenba vaccine
Pfizer announced hat TRUMENBA, the first and only FDA-approved vaccine for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B in individuals 10 through 25 years of age, is now available for order by healthcare providers in the United States.
07:29 EDTPFEPfizer less likely to pursue AstraZeneca after PD-L1 deal, says JPMorgan
Subscribe for More Information
07:18 EDTPFEWoodford confident in Astra, sees 50% chance of new Pfizer bid, Reuters reports
Investment manager Neil Woodford of Woodford Investment Management said he now has an even stronger belief in AstraZeneca (AZN), citing the company's strong product pipeline, and put the chances of a new takeover bid from Pfizer (PFE) at 50/50, reported Reuters, citing a statement from Woodford. Reference Link
06:39 EDTPFEAstraZeneca: 'Hard to comment' on whether Pfizer will come back, Reuters reports
Subscribe for More Information
November 17, 2014
14:27 EDTPFEPfizer volatility flat into investor meeting
Subscribe for More Information
11:06 EDTBMYLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
09:42 EDTPFEPfizer to host investor day
Subscribe for More Information
09:22 EDTPFEOn The Fly: Pre-market Movers
Subscribe for More Information
08:13 EDTBMY, PFEPortola, Bristol-Myers, Pfizer announce results from Phase 3 ANNEXA-A studies
Subscribe for More Information
08:10 EDTBMYBristol-Myers presents results from Phase IIIb AVERT trial at ACR
Bristol-Myers Squibb Company announced results of several new sub-analyses of the Phase IIIb AVERT trial that investigated the use of Orencia plus methotrexate in biologic and MTX-naïve citrullinated protein-positive early moderate to severe rheumatoid arthritis patients. These data were presented this week at the American College of Rheumatology 2014 annual meeting. Orencia is currently indicated in adults for moderate to severe RA. Orencia should not be administered with tumor necrosis factor antagonists and should not be used with other biologic RA drugs. One of the analyses looked at anti-CCP antibodies, which are a marker of RA and may contribute to disease progression. The analysis assessed the development of anti-CCP antibodies in patients with early rapidly progressing RA by measuring isotypes and the number of epitopes recognized after treatment with Orencia plus MTX, Orencia alone, or MTX alone. Results demonstrated Orencia plus MTX numerically reduced the concentrations of all CCP isotypes and the average number of epitopes recognized over one year of treatment more than Orencia alone or MTX alone. Over 12 months of treatment, 6.7 percent, 12.1 percent, and 7.8 percent of patients on Orencia plus MTX, Orencia alone, and MTX alone, respectively, experienced a serious adverse event and 1.7 percent, 4.3 percent and 2.6 percent led to discontinuation. Serious infections were observed in 0.8 percent of patients in the combination arm and 3.4 percent in the Orencia monotherapy arm. None of the patients in the MTX alone arm experienced a serious infection. Malignancies were reported in 0.8 percent, 1.7 percent, and 0 percent of patients in the Orencia + MTX, Orencia, and MTX arms, respectively. Additionally at ACR, investigators presented 12-month efficacy data from AVERT, including new results assessing the effect of Orencia on more clinically stringent remission criteria than DAS-defined remission, as well as new MRI data. Significantly more patients on Orencia plus MTX achieved the stringent clinical endpoint of Boolean-defined remission at 12 months.
07:16 EDTPFEMilken Institute--Faster Cures to hold a conference
Subscribe for More Information
06:43 EDTPFEAstraZeneca, Pfizer deal seen less likely after Merck transaction, Reuters says
Subscribe for More Information
05:27 EDTPFEPfizer lowers FY14 Reported EPS view to $1.40-$1.49 from $1.50-$1.59
Subscribe for More Information
05:23 EDTPFEPfizer forms strategic alliance with Merck KGaA
Subscribe for More Information
November 16, 2014
13:07 EDTBMYBristol-Myers announces results from CheckMate -066 study
Subscribe for More Information
<< 1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use